Promoter holding
64.27%
AC
Axis Clinicals Limited - Due diligence report
A 360° intelligence report on Axis Clinicals: trust score, financial health, credit view, compliance, directors, growth and distress signals…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Axis Clinicals — 360° Intelligence Report
Generated from MCA filings & public records86/100
Trust Score
Low Risk
Axis Clinicals is assessed as Low Risk with a Trust Score of 86/100. Axis Clinicals is an active public limited indian non-government company incorporated in 2007, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Axis Clinicals Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
86/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
70/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 70/100 Moderate
- Open charges exceed net worth - secured lenders rank ahead.
- Moderate gearing (D/E 38%).
- Profitable - internal accruals available.
- Externally credit-rated (BBB+).
Charges position: 9 open (1,256.45 cr) · 25 satisfied (517.22 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Sbicap Trustee Company Limited | 1 | 48.0 cr |
| Others | 6 | 48.0 cr |
| Standard Chartered Bank | 2 | 48.0 cr |
| Yes Bank Limited | 3 | 48.0 cr |
| Icici Bank Limited | 1 | 48.0 cr |
| Allahabad Bank Himayat Nagar | 1 | 48.0 cr |
Compliance Score: 93/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 2 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| LAKSHMI VARA KOKA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JAYACHANDRA REDDY ATLURI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PANIBHUSHAN REDDY BONGA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Pentyala Sai Ram | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MALLIKARJUNA REDDY KANTABATHUNI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Nisha Sahu | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| China Venka Reddy Kotta | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Naga Venkata Kesavarapu | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 8 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
5 allotment(s) · 3 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Axis Clinicals Latina Sa De Cv | Subsidiary Company | 74.00% |
| Axis Clinicals Llc, Delaware, Usa | Subsidiary Company | 74.00% |
| Sanhoc Labs Limited | Subsidiary Company | 74.00% |
| Steps Therapeutics Co., Ltd, Thailand | Subsidiary Company | 74.00% |
| Auryn Labs | Associate Company | 74.00% |
Key managerial personnel: JAYACHANDRA REDDY ATLURI (Whole-time director) · PANIBHUSHAN REDDY BONGA (Whole-time director) · Pentyala Sai Ram (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 75 · Distress 65
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Asset base grew 2.1x - capacity expansion.
Operating for 19+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Profit declined two years in a row.
9 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence82/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment79/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 9 open charge(s) of 1,256.45 cr already registered.
- Compliance record supports lending.
Investor view80/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events16 Oct 2025
Director appointed
Nisha Sahu (Company Secretary)
30 Sep 2025
Last AGM held
Annual general meeting
07 Apr 2025
Director appointed
China Venka Reddy Kotta (Director)
Director appointed
Naga Venkata Kesavarapu (Director)
31 Mar 2025
Director ceased
CHARU AGARWAL
Latest balance sheet
Filed with ROC
28 Mar 2025
Charge satisfied
Standard Chartered Bank
02 Feb 2025
Charge satisfied
Axis Bank Limited
28 Jan 2025
Charge created
Others - 40.00 cr
11 Dec 2024
Charge satisfied
Axis Bank Limited
30 Oct 2024
Director appointed
LAKSHMI VARA KOKA (Additional Director)
24 Jun 2024
Charge satisfied
Standard Chartered Bank
10 Apr 2024
Charge created
Others - 175.00 cr
13 Dec 2023
Charge created
Others - 100.00 cr
Charge created
Axis Bank Limited - 31.00 Lakh
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
8 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of BBB+ from Indiarating.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
40 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Arcadis | U72900KA2009PTC051180 | Bangalore North, Karnataka, India |
| Aecom India Global Services Private Limited | U74999HR2020PTC089820 | Dlf Qe, Haryana, India |
| Tuv India P Ltd | U74900MH1989PTC052930 | Mumbai, Maharashtra, India |
| Nuevosol Energy | U74200TG2011PTC076517 | Hyderabad, Telangana, India |
| Eci Telecom | U64202MH2003PTC193807 | Mumbai, Maharashtra, India |
| Bureau Veritas Consumer Products Services (India) Private Limited | U74900DL1996PTC079646 | Vasundhra Enclave, Delhi, India |
| Vuenow Infotech Private Limited | U72900UP2019PTC123921 | Noida, Uttar Pradesh, India |
| Silabs India Private Limited | U72900TG2020PTC139507 | Shaikpet, Telangana, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Axis Clinicals before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Axis Clinicals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 70/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Axis Clinicals - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 86/100, distress signals and MSME payment-delay disclosures - know whether Axis Clinicals pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Axis Clinicals - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Axis Clinicals an active company?
Axis Clinicals has MCA status “Active” with a compliance score of 93/100 (Low Risk).
Is Axis Clinicals financially healthy?
Axis Clinicals has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Axis Clinicals?
Its overall Trust Score is 86/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Axis Clinicals?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 8 active director(s) are on record.
Does Axis Clinicals have loans or charges against its assets?
9 open charge(s) are registered against its assets, and 25 earlier charge(s) stand satisfied.
Is Axis Clinicals up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).
Is it risky to lend to Axis Clinicals?
Its Credit Risk Score is 70/100 (Moderate). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
